Eli Lilly Makes Strides with New Weight-Loss Pill
Eli Lilly has received FDA approval for its weight-loss pill, Foundayo, making it the second oral option following Novo Nordisk's Wegovy. The medication is a once-daily pill mimicking the GLP-1 hormone and offers a convenience advantage. It's projected to capture a significant market share by 2030.
The U.S. Food and Drug Administration has greenlit Eli Lilly's new weight-loss pill, Foundayo, marking a significant expansion in the oral weight-loss drug market.
This pill takes on Novo Nordisk's reigning oral medication, Wegovy, and leverages the appetite-suppressing power of GLP-1 hormones previously targeted by injectables like Mounjaro and Zepbound.
Set for shipment starting April 6, Foundayo will be priced competitively at $149 per month and offer unmatched convenience with no intake restrictions, aiming to seize market share from injectable alternatives.
ALSO READ
-
Foundayo vs. Wegovy: A New Rivalry in Weight-Loss Medication
-
Battle of the Giants: Lilly's New Weight-Loss Pill vs. Novo Nordisk
-
Eli Lilly's Weight-Loss Pill Approval Boosts Market Standing
-
Foundayo's Breakthrough: Eli Lilly's Pill Enters Weight-Loss Market
-
Eli Lilly Challenges Trump's Drug Pricing Legislation
Google News